Abiopharma

News list

Equels Thomas K 🟢 acquired 50.0K shares (2 derivative) of AIM ImmunoTech Inc. (AIM) at $1,000.00 Transaction Date: Mar 06, 2026 | Filing ID: 009587

Full text

News bot March 10, 2026, 9:58 p.m.
🔍 Equels Thomas K (Executive)

Company: AIM ImmunoTech Inc. (AIM)

Report Date: 2026-03-06
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 2
- Holdings reported: 1
- Total shares acquired: 50,025
- Total shares held: 38,922
Detailed Transactions and Holdings:
- Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-06 | Code: H | shares_owned_after: 38,922.00
- Acquired 25 shares of Series G Convertible Preferred Stock at $1000.0 per share (Derivative)
  Date: 2026-03-06 | Code: J | Expires: 2050-03-06 | Exercise: 2026-03-06 | equity_swap_involved: 0 | shares_owned_after: 25.00 | transaction_form_type: 4 | Footnotes: F1, F2
- Acquired 50,000 shares of Class G Warrants at $1.0 per share (Derivative)
  Date: 2026-03-06 | Code: J | Expires: 2031-03-06 | Exercise: 2026-03-06 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F3
Footnotes:
- F1: Each share has a stated value of $1,000 and is convertible into 1,000 shares of common stock and was issued as part of a subscription right issued in a rights offering.
- F2: n/a - Preferred shares are perpetual.
- F3: Each warrant is exercisable for one share of common stock at an exercise price of $1.00 per share and was issued as part of a subscription right issued in a rights offering.